Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding silibinin's modes of action against HCV using viral kinetic modeling.

Journal of hepatology - 1 May 2012

Guedj Jeremie, Dahari Harel, Pohl Ralf T, Ferenci Peter, Perelson Alan S

Abstract excerpt

BACKGROUND & AIMS: Legalon® SIL (SIL) is a chemically hydrophilized version of silibinin that has exhibited high antiviral effectiveness against hepatitis C virus (HCV). Its main mode of action (MOA) remains unclear, with contradicting in vitro studies supporting either suppression of entry and cell-to-cell spread or suppression of viral RNA synthesis as the main MOA. We sought to provide new insights into SIL's...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to Models, Theoretical

Share to RNA, Viral

Share to Viral Load

Share to Virus Replication

Source

Open in PubMed Open full text

Identifiers

PMID: 22245888
DOI: 10.1016/j.jhep.2011.12.012
PMCID: PMC3328661

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding silibinin's modes of action against HCV using viral kinetic modeling.PMID 22245888Read ↗

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-lifeSemantic proximity Read ↗

Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.Semantic proximity Read ↗

Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.Semantic proximity Read ↗

A perspective on modelling hepatitis C virus infectionSemantic proximity Read ↗

HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism.Semantic proximity Read ↗

Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period.Semantic proximity Read ↗

Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.Semantic proximity Read ↗

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).Semantic proximity Read ↗

A pharmacokinetic/viral kinetic model to evaluate treatment of chronic HCV infection with a non-nucleoside polymerase inhibitor.Semantic proximity Read ↗

Assessment of the activity of directly acting antivirals and other products against different genotypes of hepatitis C virus prevalent in resource-poor countries.Semantic proximity Read ↗

Modeling Suggests a Mechanism of Synergy Between Hepatitis C Virus Entry Inhibitors and Drugs of Other ClassesSemantic proximity Read ↗

Modeling complex decay profiles of hepatitis B virus during antiviral therapy†‡Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.